S
Su Pin Choo
Researcher at Singapore General Hospital
Publications - 142
Citations - 8626
Su Pin Choo is an academic researcher from Singapore General Hospital. The author has contributed to research in topics: Hepatocellular carcinoma & Medicine. The author has an hindex of 34, co-authored 118 publications receiving 5859 citations.
Papers
More filters
Journal ArticleDOI
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry,Bruno Sangro,Thomas Yau,Todd S. Crocenzi,Masatoshi Kudo,Chiun Hsu,Tae You Kim,Su Pin Choo,Jörg Trojan,Theodore H. Welling,Tim Meyer,Yoon-Koo Kang,Winnie Yeo,Akhil Chopra,Jeffrey Anderson,Christine Dela Cruz,Lixin Lang,Jaclyn Neely,Hao Tang,Homa Dastani,Ignacio Melero +20 more
TL;DR: Durable objective responses show the potential of nivolumab for treatment of advanced hepatocellular carcinoma, and safety and tolerability for the escalation phase and objective response rate were primary endpoints.
Journal ArticleDOI
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
Apinya Jusakul,Apinya Jusakul,Ioana Cutcutache,Chern Han Yong,Jing Quan Lim,Mi Ni Huang,Nisha Padmanabhan,Vishwa Nellore,Sarinya Kongpetch,Alvin Wei Tian Ng,Ley Moy Ng,Su Pin Choo,Swe Swe Myint,Raynoo Thanan,Sanjanaa Nagarajan,Weng Khong Lim,Cedric Chuan Young Ng,Arnoud Boot,Mo Liu,Choon Kiat Ong,Vikneswari Rajasegaran,Stefanus Lie,Alvin Soon Tiong Lim,Tse Hui Lim,Jing Tan,Jia Liang Loh,John R. McPherson,Narong Khuntikeo,Vajaraphongsa Bhudhisawasdi,Puangrat Yongvanit,Sopit Wongkham,Yasushi Totoki,Hiromi Nakamura,Yasuhito Arai,Satoshi Yamasaki,Pierce K. H. Chow,Alexander Y. F. Chung,London L.P.J. Ooi,Kiat Hon Lim,Simona Dima,Dan G. Duda,Irinel Popescu,Philippe Broët,Sen-Yung Hsieh,Ming-Chin Yu,Aldo Scarpa,Jiaming Lai,Di-Xian Luo,André Lopes Carvalho,André Luiz Vettore,Hyungjin Rhee,Young Nyun Park,Ludmil B. Alexandrov,Raluca Gordân,Steven G. Rozen,Tatsuhiro Shibata,Chawalit Pairojkul,Bin Tean Teh,Patrick Tan +58 more
TL;DR: In this paper, the authors analyzed 489 cholangiocarcinoma (CCA) from 10 countries, combining whole-genome (71 cases), targeted/exome, copy-number, gene expression, and DNA methylation information.
Journal ArticleDOI
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle,Maeve A. Lowery,Rachna T. Shroff,Karl Heinz Weiss,Christoph Springfeld,Mitesh J. Borad,Ramesh K. Ramanathan,Lipika Goyal,Saeed Sadeghi,Teresa Macarulla,Anthony B. El-Khoueiry,Robin Kate Kelley,Ivan Borbath,Su Pin Choo,Do Youn Oh,Philip A. Philip,Li-Tzong Chen,Thanyanan Reungwetwattana,Eric Van Cutsem,Kun-Huei Yeh,Kristen K. Ciombor,Richard S. Finn,Anuradha Patel,Suman Sen,Dale Porter,Randi Isaacs,Andrew X. Zhu,Ghassan K. Abou-Alfa,Tanios Bekaii-Saab +28 more
TL;DR: BGJ398 is a first-in-class FGFR kinase inhibitor with manageable toxicities that shows meaningful clinical activity against chemotherapy-refractory cholangiocarcinoma containing FGFR2 fusions.
Journal ArticleDOI
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
Pierce K. H. Chow,Mihir Gandhi,Say Beng Tan,Maung Win Khin,Ariunaa Khasbazar,Janus P. Ong,Su Pin Choo,Peng Chung Cheow,Chanisa Chotipanich,Kieron Lim,Laurentius A. Lesmana,Tjakra Manuaba,Boon Koon Yoong,Aloysius Raj,Chiong Soon Law,Ian Homer Y. Cua,Rolley Rey Lobo,Catherine Teh,Yun Hwan Kim,Yun Won Jong,Ho-Seong Han,Si Hyun Bae,Hyun-Ki Yoon,Rheun Chuan Lee,Chien Fu Hung,Cheng Yuan Peng,Po-Chin Liang,Adam Bartlett,Kenneth Y.Y. Kok,Choon Hua Thng,Albert S. C. Low,Anthony S. W. Goh,Kiang Hiong Tay,Richard Hoau Gong Lo,Brian K. P. Goh,David Chee Eng Ng,Ganesh Lekurwale,Wei Ming Liew,Val Gebski,Kenneth Seck Wai Mak,Khee Chee Soo +40 more
TL;DR: In patients with locally advanced HCC, OS did not differ significantly between RE and sorafenib, and the improved toxicity profile of RE may inform treatment choice in selected patients.
Journal ArticleDOI
Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers
Waraporn Chan-on,Waraporn Chan-on,Maarja-Liisa Nairismagi,Choon Kiat Ong,Weng Khong Lim,Simona Dima,Chawalit Pairojkul,Kiat Hon Lim,John R. McPherson,Ioana Cutcutache,Hong Lee Heng,London L.P.J. Ooi,Alexander Y. F. Chung,Pierce K. H. Chow,Peng Chung Cheow,Ser Yee Lee,Su Pin Choo,Iain Beehuat Tan,Dan G. Duda,Anca Nastase,Swe Swe Myint,Bernice Huimin Wong,Anna Gan,Vikneswari Rajasegaran,Cedric Chuan Young Ng,Sanjanaa Nagarajan,Apinya Jusakul,Shenli Zhang,Priya Vohra,Willie Yu,Dachuan Huang,Paiboon Sithithaworn,Puangrat Yongvanit,Sopit Wongkham,Narong Khuntikeo,Vajaraphongsa Bhudhisawasdi,Irinel Popescu,Steven G. Rozen,Patrick Tan,Patrick Tan,Bin Tean Teh +40 more
TL;DR: Functional studies demonstrated tumor suppressive functions for BAP1 and ARID1A, establishing the role of chromatin modulators in CCA pathogenesis and indicating that different causative etiologies may induce distinct somatic alterations, even within the same tumor type.